

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|-----------------------|---|---|------------------------|------------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/560,232 |
| | | | | Filing Date | 24 March 2006 |
| | | | | First Named Inventor | Menachem RUBINSTEIN et al |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | unknown |
| Sheet | 2 | 31129 | 2 | Attorney Docket Number | 31129 |
| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | | |
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| | 10 | Kalechman et al. "The Antitumoral Effect of the Immunomodulator AS101 and Paclitaxel (Taxol) in A Murine Model of Lung Adenocarcinoma", The Journal of Immunology, 156: 1101-1109, 1996. | | | |
| | 11 | Kalechman et al. "Role of Endogenous Cytokines Secretion in Radioprotection Conferred by the Immunomodulator Ammonium Trichloro(Dioxyethylene-0-0')Tellurate", Blood, 85(6): 1555-1561, 1995. | | | |
| | 12 | Kalechman et al. "Delay of the Onset of Systematic Lupus Erythematosus Following Treatment With the Immunomodulator AS101. Association With IL-10 Inhibition and Increase in TNF- α Levels", The Journal of Immunology, 159: 2658-2667, 1997. | | | |
| | 13 | Kalechman et al. "Protective and Restorative Role of AS101 in Combination With Chemotherapy", Cnacer Research, 51: 1499-1503, 1991. | | | |
| | 14 | Kalechman et al. "Synergistic Anti-Tumoral Effect of Paclitaxel (Taxol) + AS101 in A Murine Model of B16 Melanoma: Association With Ras-Dependent Signal-Transduction Pathways", International Journal of Cancer, 86: 281-288, 2000. | | | |
| | 15 | Kalechman et al. "Radioprotective Effects of the Immunomodulator AS101", The Journal of Immunology, 145(5): 1512-1517, 1990. | | | |
| | 16 | Campfield et al. "Recombinant Mouse OB Protein: Evidence for A Peripheral Signal Linking Adiposity and Central Neural Networks", Science, 269: 546-546, 1995. | | | |
| | 17 | Pelleymounter et al. "Effects of the Obese Gene Product on Body Weight Regulation in Ob/Ob Mice", Science, 269: 540-543, 1995. | | | |
| | 18 | Halaas et al. "Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene", Science, 269: 543-546, 1995. | | | |
| | 19 | Sredni et al. "Predominance of the TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS101", Journal of the National Cancer Institute, 88(18): 1276-1284, 1996. | | | |
| | 20 | Rosenblatt-Bin et al. "The Immunomodulator AS101 Restores TH1 Type of Response Suppressed by Babesia Rodhaini in BALB/C Mice", Cellular Immunology, 184: 12-25, 1998. | | | |
| | 21 | Strassmann et al. "The Immunomodulator AS-101 Inhibits IL-10 Release and Augments TNF α and IL-1 α Release by Mouse and Human Mononuclear Phagocytes", Cellular Immunology, 176: 180-185, 1997. | | | |
| | 22 | Sredni et al. "A New Immunomodulating Compound (AS-101) With Potential Therapeutic Application", Nature, 330(6144): 173-176, 1987. | | | |
| | 23 | Sredni et al. "Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Trested With Carboplatin and Etoposide", Journal of Clinical Oncology, 13(9): 2342-2353, 1995. | | | |
| | 24 | Zhang et al. "Positional Cloning of the Mouse Obese Gene and Its Human Homologue", Nature, 372: 425-431, 1994. | | | |

| | | | |
|-----------|--|------------|--|
| Signature | | Considered | |
|-----------|--|------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.